GlassScriptPhysician profile
Debbra Ames Keegan
NPI 1689737173
$20,495.34
in general payments reported to CMS, 2019-2025
7 companies · $9,442 in 2025
The $9,442 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $71.17 · 2021: $154 · 2022: $115 · 2023: $10K · 2024: $280 · 2025: $9,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $2,732 · Food and Beverage: $1,444 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,405.00 |
| Travel and Lodging | $2,732.18 |
| Food and Beverage | $1,444.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19,723.15 | 2019-2025 | Menopur |
| Organon LLC | $235.33 | 2021-2025 | Follistim Aq, Ganirelix Acetate |
| Davol INC. | $185.87 | 2025 | Arista |
| Merck Sharp & Dohme LLC | $176.78 | 2019-2021 | |
| Emd Serono, INC. | $144.85 | 2023-2024 | |
| Abbvie INC. | $14.75 | 2019 | |
| Virtus Pharmaceuticals LLC | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbra Keegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.